Briefing Contents 简报目录
Top
Privy Council confirms just and equitable winding up of Cayman Islands exempted limited partnerships 枢密院确认开曼群岛豁免有限合伙企业可基于公平公正的理由清盘
Created Date: 04 February 2026
创作日期:04 February 2026

Privy Council confirms just and equitable winding up of Cayman Islands exempted limited partnerships

枢密院确认开曼群岛豁免有限合伙企业可基于公平公正的理由清盘

Briefing Summary:

In Aquapoint LP (in Official Liquidation) v Xiaohu Fan [2025] UKPC 56, the Privy Council confirmed that a Cayman Islands exempted limited partnership ("ELP") can be wound up on grounds that it is just and equitable to do so. This decision establishes that the well-recognised principles applicable to the winding up of companies are equally relevant to ELPs.

简报摘要:

Aquapoint LP (in Official Liquidation) v Xiaohu Fan [2025] UKPC 56 一案中,枢密院确认开曼群岛豁免有限合伙企业(exempted limited partnership简称“ELP”)可基于公平公正的理由清盘。此判决确认,适用于公司清盘的公认原则同样适用于 ELP

In Aquapoint LP (in Official Liquidation) v Xiaohu Fan [2025] UKPC 56, the Privy Council confirmed that a Cayman Islands exempted limited partnership ("ELP") can be wound up on grounds that it is just and equitable to do so. This decision establishes that the well-recognised principles applicable to the winding up of companies are equally relevant to ELPs.

Importantly, the Privy Council emphasised that the inquiry is flexible and fact-specific, and there is no requirement to establish that the ELP was founded a quasi-partnership for equitable considerations to be engaged. This clarification provides greater certainty for investors and stakeholders in an ELP.

Background facts

The petitioner was a research scientist who worked in the field of cell therapy, immunology and cell biology as an employee of the Genscript group. Genscript formed Nanjing Legend Biotechnology Co Ltd ("Legend Nanjing") as the corporate vehicle for a new project to develop novel cell therapies for the treatment of cancer and other purposes. In 2016, Legend Nanjing and the petitioner entered into an agreement, pursuant to which Legan Nanjing agreed to grant him a 10% shareholding.  

Subsequently, a Cayman Islands registered exempted limited company, Legend Biotech Corporation ("Legend Cayman") was established as the intended listing vehicle. The petitioner was persuaded to agree to terminate the 2016 agreement; he was assured that his 10% shareholding in Legend Nanjing would be "rolled over" into the arrangement involving a Cayman ELP.  Aquapoint LP ("Aquapoint") was accordingly established in 2017 to hold approximately 15% of the shares in Legend Cayman and the petitioner became a limited partner holding 65.96% interest in Aquapoint.

Following the listing of Legend Cayman on the NASDAQ exchange in 2020, the petitioner sought to withdraw his 10% indirect shareholding in Legend Cayman from Aquapoint. However, Genscript, acting in its capacity as general partner of Aquapoint, used its power under the Limited Partnership Agreement (the "LPA") to prevent him from withdrawing.

As a result, the petitioner initiated proceedings in the Cayman Islands seeking to wind up Aquapoint on just and equitable grounds. The Cayman Grand Court granted the petition and ordered Aquapoint to be wound up. It was held that the petitioner had a legitimate expectation and reasonable understanding that six months after the Legend Cayman IPO he would be entitled to have access to 10% of the shares in Legend Cayman.

An appeal against this decision was dismissed by the Cayman Islands Court of Appeal. Aquapoint then appealed to the Privy Council.

Decision of the Privy Council

The following issues were considered by the Privy Council.

What are the principles applicable in a petition to wind up an ELP? The Privy Council accepted that the principles applicable to the jurisdiction to wind up a company on the just and equitable ground would also be applicable in this instance. With reference to the English Court of Appeal authority Ebrahimi v Westbourne Galleries Ltd [1973] AC 360, the Privy Council considered that the court's task is to conclude whether, on the facts and circumstances of the particular case, there exist "considerations…of a personal character arising between one individual and another, which may make it unjust, or inequitable, to insist on leal rights, or to exercise them in a particular way" (Wesborune Galleries at p. 379 per Lord Wilberforce).

When the Privy Council turned to consider the relationship between the parties:

  • Aquapoint submitted that such relationship was regulated by contract, and that any complaints made by the petitioner should be adjudicated in accordance with the law of contract instead of through the just and equitable winding up jurisdiction. Accordingly, Aquapoint argued that the petitioner had no grounds to complain, because Genscript was simply exercising its power, as a general partner under the partnership agreement, to refuse its consent to the petitioner's request.
  • Interestingly, it was held that the entire agreement clause in the LPA does not oust the jurisdiction of the court to make a winding up order on the just and equitable ground if the circumstances of the case are such as to bring equitable considerations into play. It was held that contractual provisions of this sort are highly relevant to the issue of whether those considerations do come into play, but they are not decisive.

There was also a debate as to whether it was necessary to find that the relationship between the parties was in the nature of a quasi-partnership before the equitable considerations are brought into play. The Privy Council held that a finding of a "quasi-partnership" is an example, not a definition, of the circumstances in which equitable considerations may come into play.

The Privy Council accordingly dismissed the appeal.

Aquapoint LP (in Official Liquidation) v Xiaohu Fan [2025] UKPC 56 一案中,枢密院确认开曼群岛豁免有限合伙企业(exempted limited partnership简称“ELP”)可基于公平公正的理由清盘。此判决确认,适用于公司清盘的公认原则同样适用于 ELP

尤为重要的是,枢密院强调相关审查具有灵活性且需结合具体事实,并不要求必须证明该 ELP 是以类合伙关系设立,方可适用衡平法考量。此项澄清为 ELP 的投资人和利益相关者带来了更高确定性。

背景

申请人是一名从事细胞治疗、免疫学和细胞生物学领域研究工作的科研人员,受雇于金斯瑞 (Genscript) 集团。金斯瑞设立了南京传奇生物科技有限公司(简称“南京传奇”),作为开展新项目的企业载体,旨在研发用于治疗癌症及其他用途的新型细胞疗法。2016 年,南京传奇与申请人签订协议,约定向其授予 10% 的股权。

随后,一家在开曼群岛注册的豁免有限责任公司传奇生物科技公司 (Legend Biotech Corporation)(简称“开曼传奇”)被设立为拟上市主体。申请人被说服同意终止 2016 年协议;他被保证,其在南京传奇所持的 10% 股权将“转入”一个涉及开曼 ELP 的架构安排中。  为此,Aquapoint LP(简称“Aquapoint”)于 2017 年设立,用以持有开曼传奇约 15% 的股份,申请人则成为有限合伙人,持有 Aquapoint 65.96% 的权益。

2020 年开曼传奇在纳斯达克交易所上市后,申请人试图退出通过 Aquapoint在开曼传奇的10%间接持股。然而,金斯瑞作为 Aquapoint 的普通合伙人,依据《有限合伙协议》(Limited Partnership Agreement ,简称LPA”)赋予的权力,阻止了申请人退出。

因此,申请人向开曼群岛法院提起诉讼,请求基于公平公正的理由对 Aquapoint 进行清盘。开曼大法院批准了该申请,并下令对 Aquapoint 进行清盘。法院裁定,申请人有合法合理的理由预期,在开曼传奇首次公开发行六个月后,其将有权获得开曼传奇 10% 的股份。

针对该判决的上诉被开曼群岛上诉法院驳回。Aquapoint 随后向枢密院提出上诉。

枢密院的判决

枢密院审议了以下问题。

申请对 ELP 进行清盘所适用的原则是什么?枢密院认为,基于公平公正的理由对公司进行清盘的司法原则在本案中同样适用。参照英国上诉法院在 Ebrahimi v Westbourne Galleries Ltd [1973] AC 360 一案中的权威判例,枢密院认为法院的任务在于判断在具体案件的事实和情形下,是否存在“源于当事人之间特殊个人关系的考量因素,使得坚持法律权利或以特定方式行使该等权利构成不公平或不公正”(Westbourne Galleries 案,第 379 页,Wilberforce 勋爵语)。

当枢密院转而审视各方之间的关系时:

  • Aquapoint 主张,该等关系受合同规制,申请人提出的任何争议均应依合同法予以裁断,而非通过公平公正清盘的司法管辖权处理。据此,Aquapoint 辩称,申请人并无理由提出异议,因为金斯瑞作为合伙协议项下的普通合伙人,仅是在行使其权利拒绝同意申请人的请求。
  • 值得注意的是,法院认定LPA 中的完整协议条款并不排除法院在案件情形足以引发衡平法考量时基于公平公正的理由作出清盘令的管辖权。法院进一步指出,此类合同条款对于判断是否确实存在衡平法考量因素具有高度相关性,但并非决定性因素。

关于在适用衡平法考量之前,是否必须认定当事人之间的关系具有合伙性质,也存在争议。枢密院认为,对“合伙关系”的认定只是一个示例,而非对在何种情况下可以适用衡平法考量的定义。

枢密院据此驳回了上诉。

Please note that this briefing is intended to provide a very general overview of the matters to which it relates. It is not intended as legal advice and should not be relied on as such. © Carey Olsen 2026